Carbohydrate metabolism in patients with acromegaly and Itsenko—Cushing disease


Cite item

Full Text

Abstract

The relevance of investigating carbohydrate metabolism (CM) in patients with acromegaly and Itsenko—Cushing disease is attributable to frequent glucose metabolic disturbances, on the one hand, and to difficulties in choosing sugar-lowering therapy in these categories of patients, on the other. The efficiency of hyperglycemia treatment in these patients may be reduced due to problems in achieving remission/cure of the underlying disease and to specific therapy favoring hyperglycemia. The top-priority tasks are to search for ways of reducing the frequency of CM abnormalities in patients with neuroendocrine diseases and to elaborate sugar-lowering therapy regimens. There is a growing interest in studies of the role of the incretin system in the pathogenesis of secondary hyperglycemias associated with neuroendocrine diseases. Nevertheless, few works have been published on this subject matter because of its novelty. There is a need for a further closer study of the specific features of incretin system function and the pharmacodynamics of incretin mimetics that are potential candidates as first-line drugs to treat secondary hyperglycemias. This paper attempts to summarize the available data obtained from studies into CM in neuroendocrine diseases.

References

  1. Resmini E, Minuto F, Colao A, Ferone D. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol. 2009;46:85-89.
  2. Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaudo MC, Paoloni A, D’Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. J Clin Endocrinol Metab. 2007;92:3756-3759.
  3. Astrid Breitschafta, Ke Hub, Karina Hermosillo Reséndizb, Christelle Darsteinc, Georg Golora, (Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study. Diabet Res Clin Pract. 2014;103(3):458-465.
  4. Beverly MK Biller, Annamaria Colao, Stephan Petersenn, Vivien S Bonert and Marco Boscaro Prolactinomas, Cushing’s disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. Endocrine Dis. 2010;10:10.
  5. Rosario Pivonello Monica De Leo Pasquale Vitale Alessia Cozzolino Chiara Simeoli Maria Cristina De Martino Gaetano Lombardi Annamaria Colao: Pathophysiology of Diabetes Mellitus in Cushing’s Syndrome. Neuroendocrinology. 2010;92(suppl 1):77-81. doi: 10.1159/000314319.
  6. Arnaldi G, Anqeli A, Atkinson A, Bertranga X, Cavagnini F, Chrousus G. Diagnosis and complications of Cushing’s syndrome: a consensus treatment. J Clin Endocrinol Metab. 2003;88: 5593-5602.
  7. Findling JW, Raff H. Cushing’s syndrome: important issues in diagnosis and treatment. J Clin Endocrinol Metab. 2006;91:3746-3753.
  8. Белая Ж.Е., Рожинская Л.Я., Драгунова Н.В., Дзеранова Л.К., Марова Е.И., Арапова С.Д., Молитвословова Н.Н., Зенкова Т.С., Мельниченко Г.А., Дедов И.И. Метаболические осложнения эндогенного гиперкортицизма. Выбор пациентов для скрининга. Ожирение и метаболизм. 2013;1: 29-34.
  9. Biering H, Knappe G, Gerl H, Lochs H. Pevalence of diabetes in acromegaly and Cushing’s syndrome. Fcta Med Austriaca. 2000;27:27-31.
  10. Seckl JR, Morton NM, Chapman KE, Walker BR: Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res. 2004;5(9):359-393.
  11. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-2556.
  12. Ruzzin J, Wagman AS, Jensen J. Glucocorticoid-induced insulin resistance in skeletal muscles: defects in insulin signalling and the effects of a selective glycogen synthase kinase-3 inhibitor. Diabetologia. 2005;48:2119-2130.
  13. Vegiopoulos A, Herzig S. Glucocorticoids, metabolism and metabolic diseases. Mol Cell Endocrinol. 2007;275:43-61.
  14. Vander Kooi BT, Onuma H, Oeser JK. The glucose-6-phosphatase catalytic subunit gene promoter contains both positive and negative glucocorticoid response elements. Mol Endocrinol. 2005;19:3001-3022.
  15. Dirlewanger M, Schneiter PH, Paquot N, Jequier E, Rey V, Tappy L. Effects of glucocorticoids on hepatic sensitivity to insulin and glucagon in man. Clin Nutr. 2000;19:29-34.
  16. Kahn SE. The relative contributions of insulin resistance and beta cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46:3-19.
  17. Ullrich S, Berchtold S, Ranta F. Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes. 2005;54:1090-1099.
  18. van Raalte D, Nofrate V, Bunck M, Van Iersel T, Elassaiss Schaap J, Nãssander U, Heine R, Mari A, Dokter W, Diamant M. Acute and two-week exposure to prednisolone impair different aspects of beta-cell function in healthy men. Eur J Endocrinol. 2010;1(62):729-735.
  19. Van Raalte D, Linssen M, Ouwens M, Diamant M. Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care. 2011;34 4(2):412-417. doi: 10.2337/dc10-1677.
  20. Марова Е.И., Арапова С.Д., Белая Ж.Е., Рожинская Л.Я., Колесникова Г.С., Воронцов А.В. Болезнь Иценко—Кушинга: клиника, диагностика, лечение. Под ред. Дедова И.И., Мельниченко Г.А. Практическое руководство для врачей. М.; 2012:64.
  21. Мельниченко Г.А., Попович В., Рожинская Л.Я., Белая Ж.Е. Медикаментозная терапия болезни Иценко—Кушинга. Современное состояние проблемы. Проблемы эндокринологии. 2014;60(6):29-37. doi:http://dx.doi.org/10.14341/probl201460629-37.
  22. Pivonello R, Ferone D, Kross JM, De caro ML, Arigo M, Annunziato L, Lamberts SW. Dopamine receptoe expression and function in cortocotroph pituitary tumors. J Clin Endocrinol Metab. 2004;89:2452-2471.
  23. Stefamann L, Kovacs K, Harvarth E, Buchfelder M, Fahlbusch R. Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine Rev. 2001;14:329-336.
  24. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Melmed S, Bertherat J. Treatment of pituitary-dependent Cushing’s disease with the multi-receptor ligand somatostatin analog paseriotide (SOM230): A multi-center, phase II trial. J Clin Endocrinol Metabol. 2009;94:115-122.
  25. Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary. 2014;17(2):180-186. doi: 10.1007/s11102-013-0483-3.
  26. Fleseriu M, Biller B, Findling J. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushings syndrome. J Clin Endocrinol Metab. 2012,97:2039-2049.
  27. Alia Munir. Management of Diabetes Mellitus in Cushing’s Syndrome. Neuroendocrinology. 2010;92(suppl 1):82-85. doi: 10.1159/000314316.
  28. Панькив В.И. Акромегалия: патогенез, клиника, диагностика, методы лечения. Международный эндокринологический журнал. 2011;4(36).
  29. Colao A, Ferone F, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis and management. Endocrine Rev. 2004;25:102-152.
  30. Fieffe S, Morage I, Petrossians P, Chanson P. Diabetes in acromegaly, prevalence, risk factors and evolution: Data from the French acromegaly Registry. EJE. 2011;164:877-889.
  31. Rodrigues TC, Costerano F, Fedrizzi D, Liveira MD, Lima DB, Bosch V. Diabetes mellitus in a cohort of patients with acromegaly. Arquivos Brasilieros de Endocrinologia e Metabologia. 2011;55:714-719.
  32. Alexopoulou O, Bex M, Kaminicky P, chanson P, Maiter D. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 184 patients. Pituitary. 2013;17:81-89.
  33. Древаль А.В., Триголосова И.В., Тишенина Р.С., Бфрсуков И.А., Виноградова А.В. Распространенность сахарного диабета у пациентов с акромегалией. Проблемы эндокринологии. 2012;6:3-7.
  34. Vijayakumar A, Novosyadly R, Wu Y. Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Hormone IGF. 2010;20:1-7.
  35. Lischanka A, Waters M. How growth hormone regulates growth, obesity and sexual dimprphism. Trends Genet. 2008;24:41-47.
  36. Cho Y, Arige M, Rho J. The novel roles of liver for compensation of insulin resistance in human growth hormone transgenic rats. Endocrinology. 2006;147:5373-5384.
  37. Yakar S, Setser J, Zhao H, Glatt V. Inhibition of growth hormone action improves insulin resistance in liver of OGF-1-deficient mice. J Clin Invest. 2004;113:96-105.
  38. LeRoith D. Gender differences in metabolic disorders. Gend Med. 2009;6(Suppl 1):1-3.
  39. Fernández-Pérez L, Guerra B, Díaz-Chico JC, Flores-Morales A. Estrogens Regulate the Hepatic Effects of Growth Hormone, a Hormonal Interplay with Multiple Fates. Front Endocrinol (Lausanne). 2013;4:66. Published online 2013 Jun 3. Prepublished online 2013 Apr 17. doi: 10.3389/fendo.2013.00066.
  40. Ronchi CL, Orsi E, Giavoli C, Cappiello V, Epaminonda P, Beck-Peccoz P, Arosio M. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. Pituitary. 2011;16:51-59.
  41. Giustina A, Ambrosio MR, Beck Peccoz P, Bogazzi F, S Cannavo′, De Marinis L, De Menis E, Pivonello R. Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Invest. 2014;37:1017-1030. doi: 10.1007/s40618-014-0146-x.
  42. Melmed S, Casanueva F. Klibanski FA, Bronstein M, Chanson DP, Lamberts SW, Strasburger CJJ, Wass A, Giustina HA. Сonsensus on the diagnosis and treatment of acromegaly Complications. Pituitary. 2013;16:294-302. doi: 10.1007/s11102-012-0420-x.
  43. Melmed S, Colao A, Barkan A. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509-1517.
  44. Gerardo Guinto, Miguel Abdo, Erick Zepeda, Norma Ar´echiga: Acromegaly: Role of Surgery in the Therapeutic Armamentarium. Int J Endocrinolog. 2012;2012:ID 306094:13 pages. doi: 10.1155/2012/306094.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies